Genesis Therapeutics
Genesis Therapeutics (Genesis Molecular AI) is an AI-focused biotechnology company building GEMS (Genesis Exploration of Molecular Space), a generative and predictive AI operating system for small-molecule drug discovery. GEMS combines structure-based deep learning, language and diffusion models, and physics-based simulation (molecular dynamics and quantum chemistry) to generate and optimize molecules for complex targets, accelerating hit identification through lead optimization and candidate selection. In 2025 the company introduced Pearl, a next-generation foundation model for drug discovery. Headquartered in Burlingame, California with a laboratory in San Diego, Genesis has raised over $300M and partners with Eli Lilly, Gilead, Genentech, and Incyte while advancing its own therapeutic pipeline. It is not a public API provider: GEMS is a proprietary internal platform with no published developer portal, documentation, or API.
Genesis Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Artificial Intelligence, Machine Learning, Drug Discovery, and Biotechnology.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API